TRIALS
Avonelle X: long-term ocular and systemic safety and tolerability of faricimab
STATUS:
DESCRIPTION
This study will evaluate the long-term safety and tolerability of intravitreal faricimab in patients with neovascular age-related macular degeneration (nAMD) who have completed either of the Phase III studies (GR40306 or GR40844). Additional assessments will be conducted related to efficacy, pharmacokinetics, immunogenicity, and biomarkers.
Objectives
The primary objective is to evaluate the long-term ocular and systemic safety and tolerability of faricimab in patients who have received at least one injection of faricimab during this study, regardless of treatment or protocol adherence, based on adverse events.
Drug
Faricimab is the first bispecific intraocular drug that inhibits two disease pathways by neutralizing angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A).
Population
This study only includes patients who have completed the GR40306 (TENAYA) or GR40844 (LUCERNE) study without interruption of the study drug.
Duration
Associated Pathologies
No results found.
If you found this interesting, feel free to share it here: